[New developments in the antiarrhythmic therapy of atrial fibrillation]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a progressive condition common in the elderly with cardiovascular disease.
• AF exhibits increasing resistance to treatment, linked to electrical and structural remodeling caused by high atrial rates.
• Current therapeutic strategies include managing underlying conditions, restoring sinus rhythm, and controlling ventricular rate.

Purpose of the Study:

• To review recently introduced antiarrhythmic drugs for atrial fibrillation (AF) management.
• To discuss the mechanisms of action of dronedarone, vernakalant, and ranolazine in the context of AF pathophysiology.
• To highlight the need for novel, effective, and safe compounds due to limitations of classical antiarrhythmics.

Main Methods:

• Review of current literature on atrial fibrillation pathophysiology and treatment.
• Analysis of recently introduced pharmacological agents: dronedarone, vernakalant, and ranolazine.
• Discussion of emerging antiarrhythmic agents with atria-selective mechanisms.

Main Results:

• Classical antiarrhythmic drugs are often ineffective and associated with significant side effects.
• Dronedarone, vernakalant, and ranolazine represent newer therapeutic options for atrial fibrillation.
• Development is ongoing for agents targeting atria-specific mechanisms to minimize ventricular side effects.

Conclusions:

• There is an unmet need for safer and more effective treatments for atrial fibrillation.
• Newer agents like dronedarone, vernakalant, and ranolazine offer potential advancements in AF management.
• Future research focuses on developing drugs with improved safety profiles and targeted efficacy in atrial fibrillation.